Dihydrotestosterone and 17β-Estradiol Enhancement of In Vitro Osteogenic Differentiation of Castrated Male Rat Bone Marrow Mesenchymal Stem Cells (rBMMSCs)

FAM Abo-Aziza¹, AA Zaki², AS Amer³, RA Lotfy³

¹Department of Parasitology and Animal Diseases, Veterinary Research Division, National Research Center, Giza, Egypt
²Department of Physiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
³Department of Zoology, Faculty of Women for Arts, Science and Education, Ain Shams University, Cairo, Egypt

Corresponding Author: Faten A.M. Abo-Aziza, Department of Parasitology and Animal Diseases, Veterinary Research Division, National Research Center, Giza, Egypt
Tel: +20 33335471
Fax: +20 33370931
Email: faten.aboaziza@gmail.com

ABSTRACT

Background: In vitro impact of dihydrotestosterone (DHT) and 17β-estradiol (E2) in osteogenic differentiation of castrated rat bone marrow mesenchymal stem cells (rBMMSC) still need to be clarified.

Materials and Methods: The viability, proliferation and density of cultured rBMMSC isolated from sham operated (Sham) and castrated (Cast) male rats were evaluated. rBMMSC were cultured with osteogenic differentiating medium (ODM) in the presence of DHT (5,10 nM) and E2 (10,100 nM). Osteogenesis was evaluated by alizarin red staining and measurement of calcium deposition and bone alkaline phosphatase (B-ALP) activity.

Results: Population doubling (PD) of rBMMSC isolated from Cast rats was significantly lower (P<0.05) compared to that isolated from Sham rats. rBMMSC from Cast rats showed low scattered calcified nodule after culturing in ODM and did not cause a significant increase in calcium deposition and B-ALP activity compared to rBMMSCs from Sham rats. Exposure of rBMMSC isolated from Cast rats to DHT (5 nM) or E2 (10 nM) in ODM showed medium scattered calcified nodules with significantly higher (P<0.05) calcium deposition and B-ALP activity. Moreover, exposure of rBMMSC to DHT (10 nM) or E2 (100 nM) showed high scattered calcified nodules with higher (P<0.01) calcium deposition and B-ALP activity.

Conclusion: These results indicated that the presence of testes might participate in controlling the in vitro proliferation and osteogenic differentiation capacity of rBMMSCs. DHT and E2 can enhance the osteogenic capacity of rBMMSCs in a dose-dependent manner. Based on these observations, optimum usage of DHT and E2 can overcome the limitations of MSCs and advance the therapeutic bone regeneration potential in the future.

Keywords: rBMMSC; Dihydrotestosterone; 17β-estradiol; Osteogenesis; Castration
INTRODUCTION
Models of castration to test the function of mesenchymal stem cells (MSCs) were used mostly in preclinical prostate cancer study\(^1\). Although 10–15\% of vertebral fractures and almost 30\% of hip fractures have been recorded in men, the metabolic bone disease has been studied more intensively in women than in men\(^2\). Many investigations are focused on ovariectomized rats as a model of menopause to evaluate the risk of osteopenia-induced fractures\(^3\), while there has been a deficiency in published studies on the effect of castration\(^4\).

Rat bone marrow derived mesenchymal stem cells (rBMMSCs) are heterogeneous, pluripotent, and have multi-lineage differentiation capacity into many cell types such as osteocytes, adipocytes, chondrocytes, and muscular cells that have a major role in tissue regeneration\(^5\). Therefore, rBMMSCs applications have been broadly used in numerous clinical trials for the treatment of various disorders, including osteogenic defects\(^6\). One of the most bone defects is osteoporosis that most frequently increased the fracture risk in the elderly\(^7\).

Recently, in vivo and in vitro studies on sex hormones, including testosterone and 17β-estradiol have a raised attention because of their effects on stem cells\(^8\). Testosterone and estrogen play a vital role in bone metabolism\(^9\). Sex differences represented by the effects of these sex steroids are usually found with bone defects\(^10\). Testosterone can be converted to the more potent 5-dihydrotestosterone (DHT) as it can be converted also to estrogen that has beneficial effects on bone metabolism in males through the impact on bone remodeling, including accumulation and maintenance of bone mass\(^11\). Therefore, the attention was lately attracted to the relation of sex hormones with the changes in bone mass and biochemical competence\(^12\). In vitro osteogenic differentiation of MSCs can be affected by several factors, including culture media, type of osteogenic media, doses and types of growth factors\(^13\) and the confluence at which to passage or harvest the cells\(^14\). Among these, it was reported that osteogenic differentiation of MSCs was achieved under the effect of several endocrine and autocrine/paracrine factors including steroids\(^15\). Furthermore, several studies recorded that stem cells carry estrogen and androgen receptors\(^16\) suggesting that these sex hormones may have an effective role in the modification of stem cells differentiation\(^17\). Subsequently, the hypogonadism-associated bone loss is firmly correlated to sex steroids reduction\(^11, 18\). Although some in vitro studies reported that testosterone increases the proliferation of osteoblast progenitors, but these effects are adequately controversial\(^19\). It was also reported that E2 has a regulatory role of rBMMSCs expansion\(^20\). Interestingly, a wider range of E2 concentrations was seen to fundamentally enhance BMMSCs expansion in male rather than in female. Nonetheless, the regulatory effect of E2 on osteoblastic differentiation is still contradictory\(^21\).

Previous studies found that menopause women were protected by 17β-estradiol, and men were protected by androgens most until 60 years\(^22\). However, the functional interaction of sex steroids in osteoblast differentiation and bone formation still need to be clarified. Therefore, in the present study, to test the ideality of isolation method of rBMMSCs cell counting and viability assay were done. The proliferation of isolated rBMMSCs from sham alizarin red and castrated male rats was investigated using colony forming unit-fibroblastic number (CFU-F) and population doubling (PD) assays. The effect of castration on osteogenic differentiation was studied. Finally, the effect of two doses of DHT and E2 on in vitro osteogenic differentiation of rBMMSCs derived from castrated rats was investigated.

MATERIALS AND METHODS
Ethical approval
All procedures were performed as per to the guidelines laid down by the International Animal Ethics Committee and in accordance with the regulations stated by National Research Centre, Egypt for laboratory animals caring and use.

Animals and surgical operation
Twenty adult male Wistar albino rats of 70–80 days of an average weighted 150–200 gm were used throughout the study. Rats were obtained from the Laboratory Animal House, National Research Centre, Egypt. The rats were kept at 22–24°C and 50–60 %
humidity. Rats were housed in two groups in the animal room and were fed standard rodent ration and water *ad libitum*. Ten healthy rats were Castrated (Cast) under diethyl ether (Sigma-Aldrich, USA) anesthesia, and all steps were made to reduce the suffering of animals. Briefly, about 3 - 4 cm straight incision was made from caudal to cranial along the scrotum under sterile conditions after pushing the testes, then spermatic cord was firmly tied and then spermatic cord was cut with scissors. The incision was closed with interrupted sutures.

Ten healthy rats were incised in the scrotum and the testes were pulled without removal and considered as sham operated (Sham). After surgery, all rats were housed separately and supplied with sufficient food and water available *ad libitum*. Sham and Cast rats were killed with an anesthetic overdose of diethyl ether at 21 days’ post operation. Isolated and standardized osteotomy of femur head from Sham and Cast rats were done as described previously. Left femurs were used for histological examination while the right femurs were used for rBMMSCs isolation.

**Histological examination**

Microscopical features of bone trabeculae were visualized with hematoxylin-eosin stain for evaluating changes in femurs after castration. The left side of the femur of each rat was separated and fixed in 10% neutral buffered formalin (Sigma-Aldrich, USA), and then decalcified in decalcifying solution (24.4% formic acid and 0.5 N sodium hydroxide, Sigma-Aldrich, USA) for 5 days. Mixed decalcifying solution was replaced once a day for 3 days. The decalcified bones were embedded in paraffin (Sigma-Aldrich, USA), sectioned with a microtome, stained and examined as previously described.

**Bone marrow collection**

Bone marrow (BM) was harvested by introducing alpha minimum essential medium (α-MEM, Invitrogen, USA) in the collected right femur and flushing the contents. BM was diluted with α-MEM for rBMMSCsisolation.

**Isolation and cultivation of rBMMSCs**

Mononuclear cells (MNCs) isolation was performed by gradient centrifugation of 2 ml BM blood on the same volume of Ficoll- Histopaque®-1077 (Sigma-Aldrich, USA) for 20 minutes at 2000 rpm and room temperature. MNCs were then collected, washed twice and resuspended in α-MEM. The cells were counted using hemocytometer and 1 × 10⁶ BM derived all nucleated cells were seeded into 100 mm culture plates (Corning, USA) and incubated to adhere at 37°C in humidified atmosphere with 5% CO2. Two days later, the media was changed to discard the non-adherent cells, while the adhered cells were kept in α-MEM (Invitrogen, USA) supplemented with 20% fetal bovine serum (FBS, Lonza, Switzerland), 55 μM 2-mercaptoethanol (Lonza, Switzerland), 2 mM L-glutamine (Lonza, Switzerland) and penicillin/streptomycin (Lonza, Switzerland). Changing of the media was done twice a week and the plates were microscopically observed. After the colonies reached 80% confluence, the cells were harvested after detachment using 1 ml trypsin-EDTA 0.25%, (Lonza, Switzerland) for each plate and incubated for 5 min at 37°C in humidified atmosphere with 5% CO2. Then, α-MEM supplemented with 20% FBS was added for trypsin deactivation. The detached cells were collected in a sterile tube and centrifuged at 2000 rpm for 5 min. The pelleted cells were resuspended with 1ml α-MEM and 0.25 x 10⁶ cells were cultured in T-25 flask (Nunc, USA) and designated as passage 1 to be exposed for cell proliferation and differentiation assays.

**Cell counting**

After two weeks, the third passage of rBMMSCs derived from Sham and Cast rats were washed twice with phosphate buffer saline (PBS, PH 7.4). The cells were detached using trypsin-EDTA 0.25%, then collected and centrifuged at 2000 rpm for 5 min. The cells were suspended in 2ml α-MEM, and their number was counted in an aliquot using hemocytometer.

**Cell viability assay**

Upon reaching 80% confluence, the viability of rBMMSCs derived from Sham and Cast rats were evaluated and the dead cells were excluded using
trypan blue stain (Sigma-Aldrich, USA) \(^2\). The dead cells were stained blue, while the live cells remained unstained.

Cell proliferation assay
To determine the proliferation capacity of rBMMSCs derived from Sham and Cast rats, CFU-F assay and PD were performed.

CFU-F assay
To determine CFU-F, \(1 \times 10^6\) cells from the third passage of rBMMSCs derived from Sham and Cast rats were seeded on 100 mm culture dish. Upon reaching 80% confluence, approximately after 14 days, the cultured cells were washed with PBS, pH 7.4 and stained with 1% toluidine blue solution (Sigma-Aldrich, USA) in 2% paraformaldehyde (Sigma-Aldrich, USA). The cells were then examined under inverted microscope, and each cell group containing in excess of 50 cells was counted as colony\(^2^6\).

PD
To determine the proliferation capacity of cultured rBMMSCs derived from Sham and Cast rats, PD assay was calculated\(^2^7\). Briefly, the cells were detached using trypsin-EDTA 0.25%, and a total of \(0.25 \times 10^6\) cells from each group were seeded on culture flasks. Upon reaching 80% confluence, the cells were detached using trypsin-EDTA, and then passaged again at the same cell density. The cells were monitored, and the number was counted at every passage. PD in each passage was calculated using the following equation: \(\log_2\) (number of harvested cells / number of plated cells). Then, the final PD was calculated by accumulative addition of total numbers of each passage until the stopping of cell division.

Effect of castration on \textit{in vitro} osteogenic differentiation
The confluent rBMMSCs of Sham and Cast rats of passage 3 were cultured under osteogenic culture conditions for 3-4 weeks at 37°C in humidified atmosphere with 5% CO\(_2\) with changing the medium twice a week\(^2^8\). The osteogenic differentiation medium (ODM) was \(\alpha\)-MEM supplemented with 20% FBS, 2 mM-L-glutamine, 55 \(\mu\)M 2-mercaptoethanol, 100 \(\mu\)M L-ascorbic acid 2-phosphate (Sigma-Aldrich, USA), 2 mM\(\beta\)-glycerophosphate (Sigma-Aldrich, USA), dexamethasone (Sigma-Aldrich, USA) and 10 \(nM\) penicillin/streptomycin.

Sex steroids supplementation
rBMMSCs derived from Sham rats were cultured with ODM (Sham + ODM). rBMMSCs derived from Cast rats were exposed to OMD supplemented with different concentrations of DHT (Sigma-Aldrich, USA) and E2 (Sigma-Aldrich, USA) as follow: (1) rBMMSCs derived from Cast were cultured with ODM (Cast + ODM), (2) rBMMSCs derived from Cast were cultured with ODM supplemented with 5 \(nM\) of DHT (Cast + ODM + 5MDHT), (3) rBMMSCs derived from Cast were cultured with ODMs supplemented with 10 \(nM\) DHT (Cast + ODM + 10MDHT), (4) rBMMSCs derived from Cast were cultured with ODM supplemented with 10 \(nM\) E2 (Cast + ODM + 10nM E2), (5) rBMMSCs derived from Cast were cultured with ODM supplemented with 100 \(nM\) E2 (Cast + ODM + 100nM E2). These concentrations were chosen to evaluate the effects of DHT and E2 at low and high concentrations based upon previous dose-response studies\(^2^1\). The medium was changed twice a week and osteogenesis confirmation was done using alizarin red stain and measurement of calcium deposition and bone ALP (B-ALP) activity.

Evaluation of osteogenic differentiation
Alizarin red staining
To highlight extracellular mineralization, the osteogenic-induced cells were stained as described previously\(^2^8\). Briefly, washing of osteogenic-induced cells with PBS was done followed by fixation in 60% (v/v) isopropanol (Sigma-Aldrich, USA) for one min in 60mm dishes. The cells were rehydrated using distilled water and stained with 1% alizarin red stain, PH 4.1 (Sigma-Aldrich, USA). The cells were washed four times with distilled water after 3 min incubation at room temperature, and then they were left in the air to dry. Finally, the mineralized nodules were imaged using inverted microscope.

Calcium deposition assay
To determine osteoblastic differentiation, calcium assay was performed\(^2^9\). Seeding a fixed number of all
differentiated cells into the wells was done. The cells were washed twice with PBS and extracted off the wells in 0.5 N HCl (Sigma-Aldrich, USA). The accumulated calcium was removed from the cellular component by 5 h shaking at 4°C, then centrifuged at 2,000 rpm for 10 min. Calcium was determined in the supernatant using calcium colorimetric assay kit (Abcam, USA). Total calcium was determined by the measurement of absorbance at 575 nm and calculated from parallel prepared standard solutions and expressed as mg/well.

**B-ALP activity measurement**
Osteogenic differentiation in each group was evaluated by B-ALP activity assay as described previously. Osteogenic-induced cells were incubated for 5 min at room temperature with 20 μL/well of 0.1% Triton X-100 (Sigma-Aldrich, USA) for cell lysis. B-ALP assay kit (Abcam, USA) was used to measure B-ALP activity of the cell lysates at absorbance 405 nm using a Microplate Reader.

**Statistical analysis**
Data analysis was performed using the statistical software of Statistical Package for the Social Sciences version 19 (SPSS-19). Correlation analysis was used to obtain P values and Pearson coefficient.

**RESULTS**
The architecture of selected sections of femoral diaphysis for sham and castrated rats can be characterized by the number and thickness of trabeculae (TB) and intertrabecular spaces (Figure 1). Histological image of cancellous bone showed uniform thinning of the trabeculae in the castrated rats resulting in widening of intertrabecular spaces in the femur head (Figure 1B). After castration, thin cancellous bone trabeculae appeared as discontinuous bony ossicles separated by wide fatty bone marrow spaces (Figure 1D).

Inverted microscopical examination showed that rBMMSCs of Sham and Cast rats were isolated from BM and adhered on the culture dishes bottom. After approximately one to two weeks, rBMMSCs from Sham and Castrates continued to proliferate and propagate until reached 80% confluence. The cells in the two groups became spindle in shape with process and appeared as fibroblast, but rBMMSCs derived from Cast rats took more long time to reach 80% confluence than that derived from Sham rats as observed by inverted microscope (Figure 2).
**Cell viability**

The viability of rBMMSCS was more than 90% at 80% confluence. There was no significant difference in the viability of cells from Sham (90.74%) and Cast (90.23%) rats (Figure 3-A).

**Cell density**

rBMMSCs were isolated from Sham and Cast rats, then cultured and the cell densities per cm² culture area were calculated after 2 weeks of incubation. It was found that the cell density of rBMMSCs from Cast rats (4.212x10⁴ cells/cm²) was not significantly different than that of Sham rats (4.325x10⁴ cells/cm²) (Figure 3-B).

**CFU-F**

When rBMMSCs reached 80% confluence, they became strongly attached to the extracellular matrix and highly tended to form CFU-Fit. No significant difference was recorded between the CFU-F number of rBMMSCs from Sham and Cast rats (Figure 3-C).

**PD**

Final PD score determined the maximal potential of proliferation of cultured cells. The results showed that rBMMSCs derived from Cast rats exhibited a significantly lower final PD when compared to that from Sham rats (Figure 3-D).

**Osteogenic differentiation**

To assess the effect of castration on osteogenic differentiation of rBMMSCs, induction of *in vitro* osteogenic differentiation of rBMMSCs derived from Sham and Castrates was done and stained using the alizarin red method, as well as calcium deposition and B-ALP activity were determined. Sham +ODM showed high scattered red calcified nodules (Figure 4-A). However, Cast +ODM showed low scattered red calcified nodules (Figure 4-B) and did not cause a significant increase in calcium deposition and B-ALP activity compared to Sham + ODM (Figure 5).

Culturing of Cast +ODM +5nM DHT showed medium scattered red calcified nodules (Figure 4-C). However, these cells showed significantly higher calcium deposition (25.17 mg/well) and B-ALP activity (42.27 U/mg protein) at P<0.05 compared to that of Cast +ODM (Figure 5). Moreover, high dose of DHT (10nM) supplementation in ODM in Cast +ODM+10nM DHT showed high scattered red calcified nodules (Figure 4-D). Likewise, Cast +ODM +10nM DHT showed significantly higher calcium deposition (39.62 mg/well) and B-ALP activity (56.12 U/mg protein) at P<0.01 compared to that of Cast +ODM (Figure 5).

Furthermore, Cast +ODM +10nME2 showed medium scattered red calcified nodules by alizarin red staining (Figure 4-E). Moreover, osteogenic differentiation of Cast +ODM +100nM E2 showed high scattered red calcified nodules by alizarin red staining (Figure 4-F). In addition, ODM supplemented with 10 nM of E2 significantly increases calcium deposition (28.18 mg/well) and B-ALP (40.41 U/mg protein) at P<0.05 as well as 100 nM supplementation of E2 significantly increase calcium deposition (36.12 mg/well) and B-ALP (35.28 U/mg protein) at P<0.01 (Figure 5). The correlation of calcium deposition (mg / well), B-ALP (OD) and B-ALP ALP (U/mg protein) of rBMMSCs isolated from different groups was also done (Figure 6).
DISCUSSION

Recent research is moving away from embryonic stem cells (ESCs) due to ethics surrounding them. Laboratory attention was concentrated on stem cells derived from adult tissues. However, rBMMSCs collect the basic characteristics of stem cells, including the ability to self-renew and differentiate into multiple cell types. Commonly, the three important features allowing rBMMSCs to be isolated from various species are the plastic surfaces adherent ability, the high proliferation capacity, and the greater vulnerability to trypsin digestion compared to the other BM cells. Therefore, BMMSC was used in the present study.

rBMMSCs undergo proliferation in response to various factors. These factors may be related to the culturing process such as the optimum confluence at which to passage or harvest the cells or may be due to the donor-related effect such as sex steroids. Although rBMMSCs are promising cell types that widely investigated for their clinical uses, their reduced number in the body are usually coupled with various dysfunctions. Since sex steroids have a thoughtful impact on different cell types, the present study investigated the proliferation of rBMMSCs of castrated male rats.

The viability of rBMMSCS was more than 90% at 80% confluence. There was no significant difference in the viability of cells from Sham (90.74%) and Cast.
(90.23%) rats. It was found that the cell density of rBMMSCs from Cast rats (4.212 x 10^4 cells/cm^2) was not significantly different from that of Sham rats (4.325 x 10^4 cells/cm^2). These results are consistent with the results obtained by Al-Mutairi et al. This data collectively indicated that castration did not affect the viability and the cell density of rBMMSCs, and the variation of the effect of castration may involve the advanced process. In the present study, it was found that rBMMSCs from Sham and Cast rats continued to proliferate and propagate until they reached 80% confluence approximately after 15 and 17 days, respectively. This result was parallel to the previous study where BMSC isolated from sham and ovariectomized rats reached 80% confluences nearly at the same time. In this investigation, the cells in the two groups became spindle in shape with process and appeared as fibroblast as observed by inverted microscope. In vitro preparations of rBMMSCs are defined as a mixture of heterogenic adhered growing cells having similar spindle-shaped morphology. Several studies have reported that in vitro cultured rBMMSCs are mostly distinct subpopulations, and the minor of expanded MSCs colonies have a full proliferation potentiality, referring to functional variances of BMSC subpopulations. It was indicated in previous studies that female sex hormone, estrogen, was shared in the control of MSCs proliferation. This effect was previously characterized in stem cells derived from both male and female BM. For osteogenesis, the media used in the present study contained substances considered as stimuli such as ascorbic acid, β-glycerophosphate (β-GP) and dexamethasone. Ascorbic acid actively induced mineralization and promoted collagen synthesis. β-glycerophosphate involved in the construction of mineral hydroxyapatite within the collagenous matrix. In addition, ascorbic acid prompted ALP activity, where it split phosphate from the added β-GP, phosphate move in the cell via Na^+ transporters. In this study, to assess whether castration affected osteogenic differentiation of rBMMSCs, in vitro osteogenic differentiation of Sham and Cast rats derived rBMMSCs was induced and stained with alizarin red staining. Moreover, calcium deposition and B-ALP activity were measured. Sham + ODM showed highly scattered red calcified nodules. However, Cast + ODM showed low scattered red calcified nodules and did not cause a significant increase in calcium deposition and B-ALP activity compared to Sham + ODM. These results are in agreement with the findings of Al-Mutairi et al. in ovariectomized rats. In males, the skeletal integrity maintenance is androgen dependent and inherited or acquired testicular function disorders are usually coupled with bone loss. Definitely, congenital hypogonadism in male prompts osteoporosis that can be avoided by administering testosterone. Likewise, castration could lead to osteopenia as a result of elevated bone resorption. In rats, orchidectomy-induced bone loss has resulted from elevated endosteal bone resorption, trabecular bone loss, and increased number of osteoclasts. These alterations can be reversed by the administration of testosterone or dihydrotestosterone (DHT). In addition, the detection of the receptors of both androgen and estrogen in bone, and the in vitro conversion of testosterone into both dihydrotestosterone and estrogen in the bone of rat and human suggested that these steroids have direct potential effects on bone.

Culturing of Cast + ODM + 5nM DHT showed medium scattered red calcified nodules. However, these cells showed significantly higher calcium deposition and B-ALP activity compared to that of Cast + ODM. Moreover, high dose of DHT (10nM) supplementation in ODM showed high scattered red calcified nodules. Likewise, it showed significantly higher calcium deposition and B-ALP activity as shown in Cast + ODM + 10nM DHT compared to that of Cast + ODM. Furthermore, Cast + ODM + 10nM E2 showed medium scattered red calcified nodules by alizarin red staining. Moreover, osteogenic differentiation of Cast + ODM + 100nM E2 showed highly scattered red calcified nodules by alizarin red staining. In addition, ODM supplemented with 10 nM of E2 significantly increased calcium deposition and B-ALP and 100 nM supplementation of E2 significantly increased calcium deposition and B-ALP. Concerning the role of estrogens, there is an indication that 17β-estradiol supports osteogenic differentiation of MSCs mainly via ERα receptor.
This preference of the receptor can be referred to sex differences and individual variation of osteoblast responses of MSCs to estrogen demonstrated by ERα polymorphism\textsuperscript{59}. Supplementation of 17β-estradiol to osteogenic differentiation medium of rBMMSCs can increase bone morphogenetic protein (BMP) and osteocalcin expression and significantly increase calcium deposition\textsuperscript{50}. Estrogen also maintains bone density by suppressing bone resorption and enhancing bone formation as reported recently\textsuperscript{51}. This effect might be through their nuclear receptors\textsuperscript{52}. Martin et al.\textsuperscript{53} indicated that estrogen has an important effect in regulating differentiation of osteoblasts. Estrogen administration to ovariectomized rodent was accompanied by decrease in apoptosis of MSCs in vitro\textsuperscript{54}. In the \textit{in vitro} studies, the osteogenic differentiation of rBMMSCs was increased when estrogen was added to the media as a result of the elevation of bone morphogenetic protein expression and significant increase of calcium and ALP deposition\textsuperscript{59}. Previous studies discussed how estrogen and testosterone direct the differentiation, suggesting that the effect of estrogen on their receptors might affect the function of those cells\textsuperscript{17}. On the other hand, the function of testosterone on stem cells remains debatable. Some studies suggested that testosterone might inhibit the functions of stem cell, and anti-testosterone could reflex these effects\textsuperscript{16}. Thus, modulation of stem cells functions via sex hormones may be the goal of recent therapeutic efficacy\textsuperscript{55}. The molecular mechanism by which steroids enhance proliferation was previously mentioned by activating Notch and JNK signaling pathway and upregulation of ERs transcripts activation\textsuperscript{56,57}. However, estrogens are critical for the maintenance of bone mass in women, androgen level decrease can also lead to bone loss in men\textsuperscript{11}. Therefore, testosterone replacement is useful for bone mineral density (BMD) maintenance\textsuperscript{18}, in which both the effects of the androgen and estrogen converted from the androgen are involved\textsuperscript{11}. Testosterone to some extent differed from estrogen in previous literature. Osteogenesis was enhanced by androgen through activation of estrogen receptors via Akt activation as reported\textsuperscript{58} or through decrease insulin like growth factor-1\textsuperscript{59} that are a key regulator of androgen-mediated osteoblast differentiation. Different genomic and non-genomic pathways may be also involved in mediating these effects. The non-genomic pathways are enhanced through stimulation of src kinase by Akt activation\textsuperscript{60,61}. Testosterone administration can also activate MAP kinase signaling cascade leading to increase the expression of Raf-1 and ERK-2\textsuperscript{60}. This study emphasizes the importance to understand the distinctive effects of sex hormones and the absence of testes on bone metabolism. The availability of MSCs from multiple body sources including bone marrow and the properly simple \textit{in vitro} propagation of the cells to the desired cell type in addition to the lack of ethical problems have made these cells a favorite source for stem cell therapy and effectively overcome the limitations of MSCs. The obtained data indicated that the presence of testes might participate in controlling the \textit{in vitro} BMMSCs proliferation and osteogenic differentiation. Treatment of MSCs with DHT and E2 can enhance osteogenic capacity in a dose-dependent manner. The optimal application of sex hormones can develop the therapeutic potential of MSCs in applied bone regeneration medical practice in the future.

**COMPETING INTERESTS**

The authors declare that they have no competing interests.

**REFERENCES**

1. Logothetis C, Morris MJ, Den R, et al. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018; 37(1):189-196.
2. Cauley JA, Cawthon PM, Peters KE, et al. Risk factors for hip fracture in older men: The osteoporotic fractures in men study (MrOS). J Bone Miner Res. 2016; 31(10):1810-1819.
3. Tewari D, Khan MP, Sagar N, et al. Ovariectomized rats with established osteopenia have diminished mesenchymal stem cells in the bone marrow and impaired homing, osteoinduction and bone regeneration at the fracture site. Stem Cell Rev Rep. 2015;11(2):309-21
4. Ryu SJ, Ryu DS, Kim JY, et al. Bone mineral density changes after orchietomy using a scrotal approach in rats. Korean J Spine. 2015; 12(2):55-9.
5. Mori G, Brunetti G, Mastrangelo F, et al. Targeting Adult Mesenchymal Stem Cells Plasticity for Tissue Regeneration. Stem Cells Int. 2017; 2017: 4532179.

6. Kong L, Zhen LZ, Qin L, et al. Role of mesenchymal stem cells in osteoarthritis treatment. J Orthop Translat. 2017; 9:89-103.

7. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010; 31(3):266-300.

8. Huang CK, Lee SO, Lai KP, et al. Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatol. 2013; 57(4):1550-63.

9. Grumbach MM. Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab. 2000; 13 Suppl 6:1439-55.

10. Feng W, Cui Y, Song C, et al. Prevention of Osteoporosis and Hypogonadism by Allogeneic Ovarian Transplantation in Conjunction with Intra-Bone Marrow–Bone Marrow Transplantation. Transplantation. 2007; 84(11):1459-66.

11. Cauley JA. Estrogen and bone health in men and women. Steroids. 2015; 99(Pt A):11-5.

12. Ryu SJ, Ryu DS, Kim JY, et al. Changes in bone metabolism in young castrated male rats. Yonsei Med J. 2016; 57(6): 1386-1394.

13. Khanna-Jain R, Vuorinen A, Sándor GK, et al. Vitamin D3 metabolites induce osteogenic differentiation in human dental pulp and human dental follicle cells. J Steroid Biochem Mol Biol. 2010; 122(4):133-41.

14. Abo-Aziza FA, Zaki AA. The Impact of Confluence on Bone Marrow Mesenchymal Stem (BM-MSC) Proliferation and Osteogenic Differentiation. Int J Hematol Oncol Stem Cell Res. 2017; 11(2):121-132.

15. Gurlek A, Pittelkow MR, Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1α, 25-dihydroxyvitamin D3: implications in cell growth and differentiation. Endocr Rev. 2002; 23(6):763-86.

16. Chang CY, Hsuuw YD, Huang FJ, et al. Androgenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells. Fertil Steril. 2006; 85 Suppl 1:1195-203.

17. Crisostomo PR, Wang M, Herring CM, et al. Gender differences in injury induced mesenchymal stem cell apoptosis, expression of VEGF, TNF, and IL-6 and abrogation via TNFR1 ablation. J Mol Cell Cardiol. 2007; 42(1): 142-149.

18. Sinnesael M, Claessens F, Boonen S, et al. Novel insights in the regulation and mechanism of androgen action on bone. Curr Opin Endocrinol Diabetes Obes. 2013; 20(3):240-4.

19. Hofbauer LC, Hicok KC, Khosla S. Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. J Cell Biochem. 1998; 71(1):96-108.

20. Hong L, Zhang G, Sultana H, et al. The effects of 17-β estradiol on enhancing proliferation of human bone marrow mesenchymal stromal cells in vitro. Stem Cells Dev. 2011; 20(5):925-31.

21. Niada S, Giannasi C, Ferreira LM, et al. 17β-estradiol differently affects osteogenic differentiation of mesenchymal stem/stromal cells from adipose tissue and bone marrow. Differentiation. 2016; 92(5):291-297.

22. Cotrotchi MC, Popa MA, Simionescu M. Testosterone stimulates proliferation and preserves stemness of human adult mesenchymal stem cells and endothelial progenitor cells. Rom J Morphol Embryol. 2016; 57(1):75-80.

23. Wronska TJ, Lowry PL, Walsh CC, et al. Skeletal alterations in ovariectomized rats. Calcif Tissue Int. 1985; 37(3):324-8.

24. Eça LP, Ramalho RB, Oliveira IS, et al. Comparative study of technique to obtain stem cells from bone marrow collection between the iliac crest and the femoral epiphysis in rabbits. Acta Cir Bras. 2009; 24(5):400-4.

25. Gugjoo MB, Kinjavekar AP, Aithal HP, et al. Isolation, culture and characterization of New Zealand White rabbit mesenchymal stem cells derived from bone marrow. X Asian J Anim Vet Adv. 2015; 10(10):537-48.

26. Akiyama K, You YO, Yamaza T, et al. Characterization of bone marrow derived mesenchymal stem cells in suspension. Stem Cell Res Ther. 2012; 3(5):40.

27. Ren J, Wang H, Tran K, et al. Human bone marrow stromal cell confluence: effects on cell characteristics and methods of assessment. Cytotherapy. 2015; 17(7):897-911.

28. Kang HY, Shyr CR, Huang CK, et al. Altered TNSALP expression and phosphate regulation contribute to reduced mineralization in mice lacking androgen receptor. Mol Cell Biol. 2008; 28(24):7354-67.

29. Salasnyzk RM, Klees RF, Hughlock MK, et al. ERK signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells on collagen I and vitronectin. Cell Commun Adhes. 2004; 11(5-6):137-53.

30. Choi YS, Park SN, Suh H. Adipose tissue engineering using mesenchymal stem cells attached to injectable PLGA spheres. Biomaterials. 2005; 26(29):5855-63.

31. Oryana A, Kamali A, Moshiri A, et al. Role of Mesenchymal Stem Cells in Bone Regenerative Medicine: What Is the Evidence? Cells Tissues Organs. 2017; 204(2):59-83.

32. Kosuke K, Terasaka T, Iwata N, et al. Combined Effects of Androgen and Growth Hormone on Osteoblast Marker Expression in Mouse C2C12 and MC3T3-E1 Cells Induced...
by Bone Morphogenetic Protein. J Clin Med. 2017; 6(1): 6.
33. Al-Mutairi KSH, Tariq IA, and Zakí AA. Osteogenic / Adipogenic Differentiation of Intact and Ovariectomized Young and Adult Female Rat Bone Marrow Mesenchymal Stem Cells (BMMSC). RJPBCS; 2019. 10(2): 253-265.
34. Dominici M, Paolucci P, Conte P, et al. Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa. Transplantation. 2009; 87(9 Suppl):S36-42.
35. Russell KC, Lacey MR, Gilliam JK, et al. Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency. Bio technol Bioeng. 2011; 108(11):2716-26.
36. Di Mambro A, Ferlin A, De Toni L, et al. Endothelial progenitor cells as a new cardiovascular risk factor in Klinefelter’s syndrome. Mol Hum Reprod. 2010; 16(6):411-7.
37. Beck GR, Zerler B, Moran E. Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci U S A. 2000; 97(15): 8352–8357.
38. Suzuki A, Palmer G, Bonjour JP, et al. Stimulation of sodium-dependent phosphate transport and signaling mechanisms induced by basic fibroblast growth factor in MC3T3-E1 osteoblast-like cells. J Bone Miner Res. 2000; 15(1):95-102.
39. Vanderschueren D, Van Herck E, Suiker AM, et al. Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology. 1992; 130(5):2906-16.
40. Greenspan SL, Neer RM, Ridgway EC, et al. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1986; 104(6):777-82.
41. Stępán JJ, Lachman M, Zvěřina J, et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab. 1989; 69(3):523-7.
42. Aggarwal R, Lu J, Kanji S, et al. Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities. PLoS One. 2012; 7(6):e39365.
43. Wakley GK, Schutte HD Jr, Hannon KS, et al. Androgen treatment prevents loss of cancellous bone in the orchiectomized rat. J Bone Miner Res. 1991; 6(4):325-30.
44. Colvard DS, Eriksen EF, Keeting PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989; 86(3):854-7.
45. Vittek J, Altman K, Gordon GG, et al. The metabolism of 7α-3H-testosterone by rat mandibular bone. Endocrinology. 1974; 94(2):325-9.
46. Schweikert HU, Rulf W, Niederle N, et al. Testosterone metabolism in human bone. Acta Endocrinol (Copenh). 1980; 95(2):258-64.
47. Wang Q, Yu JH, Zhai HH, et al. Temporal expression of estrogen receptor alpha in rat bone marrow mesenchymal stem cells. Biochem Biophys Res Commun. 2006; 347(1):117-23.
48. Ge L, Cui Y, Cheng K, et al. Isopsoralen Enhanced Osteogenesis by Targeting AhR/ERα. Molecules. 2018; 23(10): 2600.
49. Berger MB, Cohen DJ, Olivares-Navarrete R, et al. Human osteoblasts exhibit sexual dimorphism in their response to estrogen on microstructured titanium surfaces. Biol Sex Differ. 2018; 9(1):30.
50. Hong L, Colpan A, Peptan IA. Modulations of 17-β estradiol on osteogenic and adipogenic differentiations of human mesenchymal stem cells. Tissue Eng. 2006; 12(10):2747-53.
51. Saito A, Nagaishi K, Iba K, et al. Umbilical cord extracts improve osteoporotic abnormalities of bone marrow-derived mesenchymal stem cells and promote their therapeutic effects on ovariectomised rats. Sci Rep. 2018; 8(1):1161.
52. Yuan FL, Xu RS, Jiang DL, et al. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways. Bone. 2015; 75:128-37.
53. Martin A, Xiong J, Koromila T, et al. Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association. Bone. 2015; 75:96-104.
54. Ayaloglu-Butun F, Terzioglu-Kara E, Tokcaer-Keskin Z, et al. The effect of estrogen on bone marrow-derived rat mesenchymal stem cell maintenance: inhibiting apoptosis through the expression of Bcl-x L and Bcl-2. Stem Cell Rev Rep. 2012; 8(2):393-401.
55. Chen FP, Hu CH, Wang KC. Estrogen modulates osteogenic activity and estrogen receptor mRNA in mesenchymal stem cells of women. Climacteric. 2013;16(1):154-60.
56. Fan JZ, Yang L, Meng GL, et al. Estrogen improves the proliferation and differentiation of hBMSCs derived from postmenopausal osteoporosis through notch signaling pathway. Mol Cell Biochem. 2014; 392(1-2):85-93.
57. Song N, Wang ZM, He LJ, et al. Estradiol-enhanced osteogenesis of rat bone marrow stromal cells is associated with the JNK pathway. Mol Med Rep. 2017; 16(6): 8589-8594.
58. Yatsu T, Kusakabe T, Kato K, et al. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells. Biol Pharm Bull. 2018; (3):394-398.
59. Chen Q, Kaji H, Kanatani M, et al. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm Metab Res. 2004; 36(10):674-8.
60. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001; 104(5):719-30.
61. Kang HY, Cho CL, Huang KL, et al. Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res. 2004; 19(7):1181-90.